Miguel Beato

Miguel Beato


Research Focus & Metrics

Academic Career Length

61Years (1966-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1995 in Cell
Verified
Journal Article
Closed access
DMDavid J. Mangelsdorf
David J. Mangelsdorf
CTCarl Thummel
Carl Thummel
MBMiguel Beato
Miguel Beato
PHPeter Herrlich
Peter Herrlich
GSGünther Schütz
Günther Schütz
RERonald M. Evans
Ronald M. Evans

1 February 1989 in Cell
Verified
Journal Article
Closed access
MBMiguel Beato
Miguel Beato

1 December 1995 in Cell
Verified
Journal Article
Closed access
MBMiguel Beato
Miguel Beato
PHPeter Herrlich
Peter Herrlich
GSGünther Schütz
Günther Schütz

1 April 1984 in Nature
Verified
Journal Article
Closed access
PDF file
MKMichael Karin
Michael Karin
AHAlois Haslinger
Alois Haslinger
HHHeidi Holtgreve
Heidi Holtgreve
RRRobert I. Richards
Robert I. Richards
PKPaul Krauter
Paul Krauter
MBMiguel Beato
Miguel Beato

1 August 1983 in Nature
Verified
Journal Article
Closed access
CSClaus Scheidereit
Claus Scheidereit
SGSabine Geisse
Sabine Geisse
HWHannes M. Westphal
Hannes M. Westphal
MBMiguel Beato
Miguel Beato

1 April 1998 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
Antimo MigliaccioAntimo Migliaccio
Antimo Migliaccio
DPDomenico Piccolo
Domenico Piccolo
Gabriella CastoriaGabriella Castoria
Gabriella Castoria
MDMarina Di Domenico
Marina Di Domenico
ABAntonio Bilancio
Antonio Bilancio
FAFerdinando Auricchio
Ferdinando Auricchio
The molecular mechanisms by which ovarian hormones stimulate growth of breast tumors are unclear. It has been reported previously that estrogens activate the signal‐transducing Src/p21 ras /Erk pathway in human breast cancer cells via an interaction of estrogen receptor (ER) with c‐Src. We now show that progestins stimulate human breast cancer T47D cell proliferation and induce a similar rapid and transient activation of the pathway which, surprisingly, is blocked not only by anti‐progestins but also by anti‐estrogens. In Cos‐7 cells transfected with the B isoform of progesterone receptor (PRB), progestin activation of the MAP kinase pathway depends on co‐transfection of ER. A transcriptionally inactive PRB mutant also activates the signaling pathway, demonstrating that this activity is independent of transcriptional effects. PRB does not interact with c‐Src but associates via the N‐terminal 168 amino acids with ER. This association is required for the signaling pathway activation by progestins. We propose that ER transmits to the Src/p21 ras /Erk pathway signals received from the agonist‐activated PRB. These findings reveal a hitherto unrecognized cross‐talk between ovarian hormones which could be crucial for their growth‐promoting effects on cancer cells.